Eledon Pharmaceuticals (ELDN) Income from Continuing Operations (2013 - 2026)
Eledon Pharmaceuticals (ELDN) reported Income from Continuing Operations of 21181000.0 for Q1 2026, down 17.91% on a YoY basis from 25801551.77 in Q1 2025, and down 11.07% quarter-over-quarter from 19070000.0 in Q3 2025.
Eledon Pharmaceuticals (ELDN) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Eledon Pharmaceuticals has reported Income from Continuing Operations for 14 years, with the latest figure at 21181000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 17.91% year-over-year to 21181000.0; the trailing twelve-month figure through Mar 2026 stood at 82948000.0 (down 468.02% YoY), and the FY2025 full-year result was 45617000.0, down 26.07% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 21181000.0, down from 19070000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 38373000.0 in Q4 2024, with the low at 58384000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 12680937.5 across 5 years, with a median of 11154000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 306.68% — and 2024, when it soared 368.59%.
- Eledon Pharmaceuticals' Income from Continuing Operations stood at 58384000.0 in 2022, then surged by 114.03% to 8189000.0 in 2023, then jumped by 368.59% to 38373000.0 in 2024, then sank by 149.7% to 19070000.0 in 2025, then decreased by 11.07% to 21181000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 21181000.0 (Q1 2026), 19070000.0 (Q3 2025), and 24733000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Eledon Pharmaceuticals | 439.58 Mn | 223.54 Mn | - | -21.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.18 Mn |
| Sep 30, 2025 | -19.07 Mn |
| Jun 30, 2025 | -24.73 Mn |
| Mar 31, 2025 | -17.96 Mn |
| Dec 31, 2024 | 38.37 Mn |
| Sep 30, 2024 | -20.51 Mn |
| Jun 30, 2024 | -14.50 Mn |
| Mar 31, 2024 | -10.87 Mn |
| Dec 31, 2023 | 8.19 Mn |
| Sep 30, 2023 | -11.20 Mn |
| Jun 30, 2023 | -10.35 Mn |
| Mar 31, 2023 | -11.11 Mn |
| Dec 31, 2022 | -58.38 Mn |
| Sep 30, 2022 | -10.47 Mn |
| Jun 30, 2022 | -9.25 Mn |
| Mar 31, 2022 | -9.86 Mn |
| Dec 31, 2021 | 28.25 Mn |
| Sep 30, 2021 | -9.82 Mn |
| Jun 30, 2021 | -7.38 Mn |
| Mar 31, 2021 | -8.50 Mn |